Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
Similarly results obtained in our lab
2024-09-14
Similarly, results obtained in our lab using experimental diabetic encephalopathy induced by streptozotocin (STZ) in C57BL-6 mice showed that the hippocampus of the diabetic animals exhibited reactive gliosis, neuronal loss, NF-kB signaling activation as well as high levels of IL-1β and vascular end
-
Introduction Induction of long term potentiation LTP the
2024-09-14
Introduction Induction of long-term potentiation (LTP), the cellular correlate of learning and memory, triggers profound changes in the structure and function of excitatory synapses by increasing dendritic spine size and synaptic strength. Significant progress has been made in understanding the int
-
TC 14012 synthesis br Introduction Chronic kidney disease CK
2024-09-14
Introduction Chronic kidney disease (CKD) is a worldwide public health problem. This problem is even worse in socioeconomically deprived countries because lower income and social deprivation are associated with higher incidence of reduced GFR, progressive kidney function loss and end stage renal
-
Both AD and dyslipidemias are global public health problems
2024-09-14
Both AD and dyslipidemias are global public health problems, and an increase in their incidence over the next decades is expected. Among many triggering elements, the increase in life expectancy is one of the main risk factors associated with the increase in the incidence of AD. Meanwhile, dyslipide
-
Compounds and with potent ALR inhibitory activity were also
2024-09-14
Compounds , and with potent ALR2 inhibitory activity were also tested for their inhibition ability against ALR1, as shown in . They all showed low activity with inhibition percentages no more than 45% at the concentration of 10μM, demonstrating good selectivity for ALR2. To evaluate the antioxidant
-
Since non lipoprotein derived free
2024-09-14
Since non-lipoprotein-derived free cholesterol is recycled from the plasma membrane through the endosomal system through receptor-independent mechanisms, we wanted to determine whether ABCA2 could alter the trafficking of this source of free cholesterol. Our approach was to measure the effect of mob
-
hydroxydopamine OHDA is a selective catecholaminergic neurot
2024-09-14
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and
-
LJH685 Similarly Dilma et al tried to assess the diagnostic
2024-09-14
Similarly Dilmaç et al. [16] tried to assess the diagnostic value of adenosine deaminase activity in sputum of patients with pulmonary tuberculosis, their aim was to determine and compare sputum ADA activity in pulmonary tuberculosis, lung cancer and chronic obstructive pulmonary disease (COPD) pati
-
br Conflict of interest br Ethics committee
2024-09-14
Conflict of interest Ethics committee Introduction Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is characterized by impaired function and differentiation of T, B, and natural killer (NK) cells. Non-immunological abnormalities may also occur, including fa
-
A high throughput small molecule ACK biochemical inhibition
2024-09-14
A high-throughput small molecule ACK1 biochemical inhibition screen was performed in-house and led to the identification of 1μM inhibitor furanopyrimidine (). Further binding studies found ciprofloxacin to be both ATP-competitive and reversible. Early structure-activity relationship (SAR) work wa
-
ML385 Both subcutaneous s c and mucosal administration
2024-09-14
Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel
-
The next level of possible correlation and comparison betwee
2024-09-13
The next level of possible correlation and comparison between the α7 and 5HT3 receptors is at the subunit arrangement and protein folding. Crystal structures of the nicotinic and serotoninergic VEGFR Tyrosine Kinase Inhibitor II australia receptors [45], [46] reinforced the concept of similarities
-
br Introduction Nausea and vomiting are among the most distr
2024-09-13
Introduction Nausea and vomiting are among the most distressing side effects associated with chemotherapy in cancer patients (Billio et al., 2010). Severe emesis can negatively affect a patient's nutritional state, ability to work and motivation, which can, in turn, interfere with the clinical co
-
Tariquidar methanesulfonate, hydrate At present drugs that s
2024-09-13
At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi
-
Small kinase inhibitors have been developed
2024-09-13
Small kinase inhibitors have been developed to block AXL by interacting with the kinase cytoplasmic ATP binding site. Up to date, no AXL selective kinase inhibitors are marketed. As depicted in , some marketed kinase inhibitors such as Bosutinib and Cabozantinib or kinase inhibitors in clinical pha
15237 records 52/1016 page Previous Next First page 上5页 5152535455 下5页 Last page